Siemens Healthineers Faces a Reckoning: Diagnostics Sale, Spin-Off Delays, and a Stock at Rock Bottom

Siemens Healthineers shares hit 52-week lows as it weighs €6B diagnostics sale, faces US tariffs, and delays spin-off from parent Siemens.

Siemens Healthineers is navigating one of its most turbulent periods in recent memory, with its share price plumbing depths not seen in over a year and the company weighing a radical overhaul of its business structure. The stock, currently trading at €35.05, has shed roughly a fifth of its value since January and sits just a hair above its 52-week low of €33.80 — a level that puts it 27% below where it stood 12 months ago.

The immediate trigger for the latest leg down came from across the Atlantic. GE HealthCare, a key US rival, slashed its own forecast, blaming an extra $250 million in costs tied to higher chip, energy, and transport prices. The warning dragged down the entire med-tech sector, and Siemens Healthineers was caught in the undertow. But the pressure on the German group goes far beyond sector contagion.

A €6 Billion Exit Strategy Takes Shape

Behind the scenes, management is exploring a dramatic shake-up: the sale of its diagnostics division to private equity buyers. The unit, which has long acted as a drag on group performance, could fetch around €6 billion. In the first quarter alone, diagnostics revenues slipped roughly 3%, weighed down by weak demand in China — a market that continues to cause headaches across the industry.

A disposal would serve a dual purpose. It would offload the company’s thinnest-margin business while also helping to chip away at a debt pile that stands at roughly €14 billion. The imaging and Varian cancer therapy segments would be left untouched. That said, no final decision has been made — management could still opt to keep the division in-house.

Tariffs, Currency Headwinds, and Austerity at Home

The operating environment is hardly cooperative. New US tariffs are expected to hammer adjusted EBIT by around €400 million this year, while unfavourable currency moves could cost another €200 million to €250 million. On the home front, Germany’s planned statutory health insurance reform aims to squeeze €20 billion in savings by 2027, with over 40% of that falling on hospitals. That is already crimping spending on new medical equipment.

The technical picture reflects the gloom. The relative strength index has sunk to 28.6 — deep in oversold territory — and the stock is trading nearly 20% below its 200-day moving average. This is less a panic sell-off than a steady re-rating of an entire sector under pressure.

The Spin-Off Slips Further Away

Investors hoping for a clean break from parent Siemens will have to wait longer than expected. The conglomerate plans to put the spin-off to a vote at its annual general meeting in February 2027, under which Siemens shareholders would receive Healthineers shares directly. The parent intends to transfer 30% of its stake, surrendering its majority control.

Many in the market had hoped for an extraordinary shareholder meeting in the first half of 2026. That timetable has now been pushed back by nearly a year, dashing expectations of a near-term catalyst.

What the May Numbers Must Deliver

All eyes are now on May 7, when Siemens Healthineers reports its second-quarter results. In the first quarter, comparable revenue grew 3.8% to €5.40 billion, while adjusted earnings per share came in at €0.49 — 3% below the prior-year level. Imaging and precision therapy held up well, but diagnostics continued to weigh on the overall picture.

The company has so far stuck to its full-year guidance: comparable revenue growth of 5% to 6% and adjusted EPS of €2.20 to €2.40. Whether that range survives the combination of tariff pressure, currency headwinds, and weak Chinese demand is the question the market will be asking. Investors will also be listening closely for any official comment on the diagnostics sale talks.

Analysts See a Turnaround — Eventually

Despite the share price collapse, the analyst community remains broadly bullish. JPMorgan reaffirmed its "overweight" rating on April 30 with a price target of €61.30 — nearly double the current level. Barclays sees fair value at €55.00 and rates the stock a "buy." The consensus target sits around €54, implying more than 50% upside.

The logic is straightforward: a fully independent company with a broader free float should attract a wider investor base. But both houses acknowledge that near-term catalysts are thin on the ground. The May 7 results will provide the next data point — and possibly the next inflection point — for a stock that has seen little but bad news for months.